Findings

What do systematic reviews say?

50 questions · 50 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 16 · 32%GRADE not reported 4 · 8%Very low 12 · 24%Low 10 · 20%Moderate 8 · 16%High 0 · 0%

Propionyl‐L‐carnitine vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in disability score · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Muscle strength · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in quality of life · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in pulmonary function · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Adverse events related to treatment · non‐ambulatory children with SMA types II and III

Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.32 [0.92, 1.89]
1 study · 61 participants
Moderate